Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats

被引:29
作者
Jenkins, Trisha A. [1 ]
机构
[1] Queens Univ Belfast, Div Psychiat & Neurosci, Belfast BT9 7BL, Antrim, North Ireland
关键词
Angiotensin; Angiotensin receptor antagonist; Angiotensin converting enzyme; Angiotensin converting enzyme inhibitor; Dopamine; Serotonin;
D O I
10.1016/j.neulet.2008.08.021
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The extensive clinical experience of angiotensin converting enzyme inhibitors and angiotensin AT, receptor antagonists as anti hypertensive agents provide numerous examples of anecdotal evidence of improvements in cognition and mood. This study aimed to determine the effect of chronic treatment with the angiotensin converting enzyme inhibitor, perindopril, and the angiotensin AT, receptor antagonist, candesartan, on central neurotransmitter levels in the rat. Perindopril (1.0 mg/kg/day) or candesartan (10 mg/kg/day) was administered via the drinking water at for I week, while controls received water alone. At the end of treatment rats were sacrificed, brains removed and discrete regions dissected and analysed for noradrenaline, dopamine and its major metabolites, and serotonin content. As shown previously we found an increase in striatal dopamine levels after perindopril treatment, though this did not extend to the mesolimbic system with neurotransmitter levels unchanged in the hippocampus, nucleus accumbens and frontal cortex. Conversely, candesartan administration produced no change in dopamine, but significant decreases in both DOPAC and HVA in the striatum. In addition chronic candesartan infusion produced a significant increase in the levels of hippocampal noradrenaline and serotonin; and frontal cortex serotonin content. These results demonstrate that while angiotensin converting enzyme inhibitors and angiotensin AT, receptor antagonists act as antihypertensives by affecting the renin-angiotensin system, they have divergent actions on brain neurochemistry. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:186 / 189
页数:4
相关论文
共 54 条
[1]   Angiotensin receptors in the nervous system [J].
Allen, AM ;
Moeller, I ;
Jenkins, TA ;
Zhuo, J ;
Aldred, GP ;
Chai, SY ;
Mendelsohn, FAO .
BRAIN RESEARCH BULLETIN, 1998, 47 (01) :17-28
[2]  
Ambrosioni E, 2007, AM J CARDIOVASC DRUG, V7, P17, DOI 10.2165/00129784-200707010-00002
[3]   Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: Analysis of published clinical data [J].
Amenta, F ;
Mignini, F ;
Rabbia, F ;
Tomassoni, D ;
Veglio, F .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2002, 203 :147-151
[4]   Neurotensin agonists - Potential in the treatment of schizophrenia [J].
Boules, Mona ;
Shaw, Amanda ;
Fredrickson, Paul ;
Richelson, Elliott .
CNS DRUGS, 2007, 21 (01) :13-23
[5]   Ability of angiotensin II to modulate striatal dopamine release via the AT(1) receptor in vitro and in vivo [J].
Brown, DC ;
Steward, LJ ;
Ge, J ;
Barnes, NM .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (02) :414-420
[6]   The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency [J].
Brugts, Jasper J. ;
Boersma, Eric ;
Chonchol, Michel ;
Deckers, Jaap W. ;
Bertrand, Michel ;
Remme, Willem J. ;
Ferrari, Roberto ;
Fox, Kim ;
Simoons, Maarten L. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (22) :2148-2155
[7]  
CHAI SY, 1993, ARZNEIMITTEL-FORSCH, V43-1, P214
[8]   Therapeutic potential of angiotensin receptor blockers in hypertension [J].
Cheung, Bernard M. Y. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (06) :625-635
[9]   Serotoninergic regulation of emotional and behavioural control processes [J].
Cools, Roshan ;
Roberts, Angela C. ;
Robbins, Trevor W. .
TRENDS IN COGNITIVE SCIENCES, 2008, 12 (01) :31-40
[10]   Prejunctional angiotensin receptors involved in the facilitation of noradrenaline release in mouse tissues [J].
Cox, SL ;
Trendelenburg, AU ;
Starke, K .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 127 (05) :1256-1262